NRx Pharmaceuticals, Inc. (NRXP)
Oxford Ledge is still expanding full research coverage of NRXP. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
NRx develops NMDA-targeted psychiatric drugs and operates HOPE, a clinical care platform for treatment-resistant depression and PTSD.
SEC filings
- 8-K Entry into material agreement; Other material event; Financial statements and exhibits 2026-06-04
- 8-K Other material event; Financial statements and exhibits 2026-06-02
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 8-K Departure/election of directors or officers; Shareholder vote results; Financial statements and exhibits 2026-03-24
- 10-K Annual financial report with audited statements 2026-03-23
Source: SEC EDGAR.
Annual results
5 years of annual figures for NRXP, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$28.6M | — |
| 2024 | $0 | -$25.1M | — |
| 2023 | $0 | -$30.1M | — |
| 2022 | — | -$39.8M | -$0.60 |
| 2021 | — | -$93.1M | -$1.98 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for NRXP. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open NRXP in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.